Tysabri - (300 mg; Vial)

Generic Name	Natalizumab	Innovator	Biogen
Dosage	300 mg; Vial	Branded US Sales	More Than $1000 mn
Probable FTF	None	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	TYSABRI is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
***** ******			**** ******	****	*** ****** *** ****
****** - *********			*******	****	*** ***** ** *******

Chronology Of Events